Compare Cassava Sciences Inc (FLNA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs VF Corp — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while VF Corp trades at $17.27 (market cap $6.76B). The key difference: VF Corp is far larger — about 127.2× Cassava Sciences Inc's market cap, and VF Corp pays a 2.09% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VFC | |
|---|---|---|
Market Cap | $53.14M | $6.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $21.55 |
52-Week Low | $1.09 | $11.66 |
Enterprise Value | -$33.43M | $10.91B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
VFC trades at $17.31, up 3.84% today, with a bullish technical signal and recent earnings beats in Q3 and Q4 2025. The company shows improving cash flow trends for 2026 and reduced debt-to-asset ratio to 42.42% in 2025. Revenue declined to $9.50B in 2025, but net income margin is projected to turn positive at 2.65% in 2026. Analyst consensus price target is $19.33, with 43.1% buy ratings.
Outlook suggests potential upside from current levels amid turnaround efforts, but risks include volatile earnings, high debt, and weak consumer sentiment. Investment opportunity hinges on execution of brand improvements and debt reduction, with near-term support at $17.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
